Lumida
/ELVN
⌘K
Enliven Therapeutics Inc

Enliven Therapeutics Inc

ELVN
$54.32USD↓-3.40%-1.91 today

MARKET CAP

4.0B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$54 – $57

52W RANGE

$15
$62

AI Summary

Stalk
TrimMedium

ELVN is in a Stage 4 decline confirmed by a decisive support failure below the 9/20 EMAs, reinforcing a medium-term bearish bias. Price is extended and oversold, so timing is neutral—defer execution and look to sell into resistance around the broken $56.20–$57.50 zone on any bounce.

  • ↑Stifel maintains Buy rating with $82 price target
  • ↑Cash position of $895.2M funds R&D runway through 2030
  • ↓Q2 2026 net loss of $32.5M ($0.49/share) highlights profitability strain
Full analysis →
Sales, Adj.
No data
Gross Profit, Adj.
No data
EBITDA, Adj.
EBIT
Net Income